VANCOUVER, BC, April 16, 2021 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class oncology and antiviral therapeutic, is announcing robust preclinical efficacy data against a wide range of COVID-19 variants. New in vitro research completed by Bold Therapeutics’ collaborators at the University of British Columbia and Western University showed that BOLD-100 consistently reduced viral concentrations in multiple COVID-19 variants, including … Continue reading Bold Therapeutics’ BOLD-100 Effective In Vitro Against COVID-19 Variants →

Northview Lifesciences would like to congratulate Perimeter on their FDA Breakthrough Device Designation for the Optical Coherence Tomography (OCT) Imaging System with ImgAssist AI. The OCT Imaging System offers real time intra-operative evaluation of breast cancer tumor margins during lumpectomies and will give surgeons tomographical confirmation of cancer removal. The goal of the FDA Breakthrough … Continue reading Northview Congratulates Portfolio Company Perimeter Medical Imaging AI Inc. on FDA Breakthrough Device Designation →

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30 p.m. ET. In order to participate in the audio … Continue reading Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference →

April 12, 2021 – In our COVID world, we all need to get creative in building new ways to safely and effectively come together. The pandemic is showing us that Canada needs strong life sciences industry leaders and a dynamic and well-connected national ecosystem like never before. That’s why adMare BioInnovations is proud to announce … Continue reading adMare BioInnovations launches Canada’s first & only digital life sciences community →

April 9, 2021 – AstraZeneca will share updates from the Company’s innovative early oncology pipeline across multiple strategic platforms during the virtual American Association of Cancer Research (AACR) Annual Meeting, 10 to 15 April 2021. Five presentations will unveil the next-generation PARP1 selective inhibitor AZD5305, underscoring AstraZeneca’s commitment to advancing therapies that selectively kill cancer … Continue reading AstraZeneca accelerates early oncology pipeline across key strategic scientific platforms at AACR →

The BC Government has launched a new $10 million program to help small and medium-sized BC manufacturers with commercialization or processing of value-added goods. The BC Accelerating Manufacturing Scale-Up Grant program will provide grants of between $50,000 and $250,000 to individual eligible companies, and grants of up to $500,000 to groups of companies working in … Continue reading Province of BC announces program to accelerate manufacturing →

BURNABY, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will present a corporate overview and participate in the following virtual investor conferences: 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 am ET. The live webcast of the fireside chat can be … Continue reading Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences →

VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in lupus nephritis (LN). The data were shared at the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings by Anca D. Askanase, M.D., … Continue reading Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings →

SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient has been dosed in the AFFINITY Study, a phase 2 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of … Continue reading Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases →

April 7th, 2021 Victoria, B.C Axolotl Biosciences – a spin-off company from the University of Victoria  claimed the top Judge’s Pick Award during the FASTPITCH competition held at the 2021 Life Science Innovation Northwest Conference. In this competition, twelve life science early-stage companies competed for a $5,000 judges-pick prize and a $1,000 audience-pick prize. Judges … Continue reading Axolotl Biosciences wins the Judge’s Choice Prize at the FASTPITCH Competition held at 2021 Life Science Innovation Northwest Conference →